- The trend backdrop is active with a 5-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
COHANCE
NSI
Week ended 07 Aug 2026
Weekly Investor Report
COHANCE LIFESCIENCES LTD · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
445.8 INR
4.8%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 14.5% above the Trend Line and sits at 23.2% of its 52-week range. The latest completed week returned 4.8%, after a -1.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is expensive relative to peers. The latest news-sentiment score is 46/100.
Setup score
38
out of 100
Latest Close
445.8 INR
7 Aug 2026
1W Return
4.8%
latest completed week
4W Return
-1.4%
short-term follow-through
12W Return
5.3%
quarterly tape
Trend Breadth
9.6%
5 of 52 weeks active
Volume Ratio
2.0x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
4.8%
Latest completed week; four-week move -1.4%.
Indicator stack
23/52
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
46/100
32 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 14.5% above the Trend Line and sits at 23.2% of its 52-week range. The latest completed week returned 4.8%, after a -1.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3012-week average 0.30
12-week confirmation
Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.30Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -1.4% over four weeks, 5.3% over 12 weeks, and -52.2% over one year. The current trend has remained active for 5 consecutive weeks.
Performance by holding period
Active trend streak5 weeks
Active weeks in one year5
Trend breadth9.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.35Latest activity-pressure read.
Pressure change-60.4%Four-week change in activity pressure.
Leadership-16.11Latest relative-leadership reading.
RS change20.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 88%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value10/100Relative valuation strength. Underlying universe rank 91; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum2/100Medium-term price momentum. Underlying universe rank 99; rank 1 is best.
Growth2/100Revenue and earnings growth. Underlying universe rank 99; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework5/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 95.2x Price divided by trailing earnings.
- Price / sales
- 7.5x Market value relative to trailing revenue.
- EV / EBITDA
- 40.6x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 0.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 70.8% Gross profit retained from each unit of revenue.
- Operating margin
- 10.6% Operating profit retained from revenue.
- Free-cash-flow margin
- 6.5% Free cash flow generated from revenue.
- Return on invested capital
- 4.2% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -13.0% Latest one-year revenue growth.
- EPS growth
- -75.5% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -58.4% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.2% Net share repurchases relative to market value.
- Shareholder yield
- -0.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.8x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment46/100
Weighted news tone is neutral across 32 relevant articles.
5 positive · 20 neutral · 7 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-57.1%Distance below the 52-week high.
13-week volatility5.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+34.2%Week of 1 May.
Worst week-13.3%Week of 15 May.
Latest week+4.8%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains8
Flat weeks0
Modest losses7
Sharp losses6
Recent vol5.8%13-week weekly-return volatility.
Base vol8.1%52-week weekly-return volatility.
Up/down split18/34Count of positive and negative weeks in the 52-week window.
Average skew6.2% / -5.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank62 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank49 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape34/100
Trend, activity pressure, participation, and risk combine to a 34/100 tape read.
Indicator analysis45/100Latest 12-week confirmation: trend 5/12, activity pressure 12/12, relative leadership 0/12.
Activity pressure 0.30; No reversal markers Factors13/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 80; Small Cap Core rank 96 SVQF5/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1501.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment46/100Weighted news tone is neutral across 32 relevant articles.
Navin Fluorine, Cohance Lifesciences, Neuland Labs shares surge amid spike in trading activity Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 445.8 INR | 4.8% | 389.2 INR | 779.0 INR | 0.35 | -16.11 | 8.9M | On |
| 31 Jul 2026 | 425.2 INR | 2.0% | 390.2 INR | 779.4 INR | 0.50 | -20.77 | 1.4M | On |
| 24 Jul 2026 | 417.1 INR | -5.6% | 393.3 INR | 779.8 INR | 0.69 | -21.81 | 2.4M | On |
| 17 Jul 2026 | 441.9 INR | -2.2% | 397.3 INR | 780.3 INR | 0.86 | -20.68 | 5.2M | On |
| 10 Jul 2026 | 451.9 INR | -0.6% | 400.5 INR | 780.5 INR | 0.89 | -20.15 | 2.7M | On |
| 3 Jul 2026 | 454.5 INR | -0.8% | 403.3 INR | 780.8 INR | 0.90 | -21.32 | 403.8K | Off |
| 26 Jun 2026 | 458.0 INR | 12.9% | 406.3 INR | 781.0 INR | 0.88 | -21.39 | 0 | Off |
| 19 Jun 2026 | 405.9 INR | -4.9% | 409.8 INR | 781.1 INR | 0.85 | -31.20 | 777.6K | Off |
| 12 Jun 2026 | 427.0 INR | -1.0% | 415.9 INR | 781.7 INR | 0.93 | -27.68 | 350.8K | Off |
| 5 Jun 2026 | 431.1 INR | -0.1% | 422.2 INR | 782.0 INR | 0.97 | -27.44 | 1.6M | Off |
| 29 May 2026 | 431.5 INR | 3.1% | 431.4 INR | 782.3 INR | 1.09 | -29.20 | 3.0M | Off |
| 22 May 2026 | 418.5 INR | -1.1% | 442.2 INR | 782.6 INR | 1.25 | -33.02 | 16.5M | Off |
| 15 May 2026 | 423.2 INR | -13.3% | 457.4 INR | 783.0 INR | 1.22 | -33.33 | 14.5M | Off |
| 8 May 2026 | 488.2 INR | 1.0% | 473.0 INR | 783.3 INR | 1.28 | -26.12 | 21.8M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.